CClinicalTrials.gg
CompletedNCT07392463Updated Feb 6, 2026

Artificial Intelligence Versus Virtual Reality Teaching for Children and Adolescents With ADHD

An interventional study of Artificial Intelligence-Assisted Teaching and Virtual Reality-Based Smart Classroom Teaching in Attention Deficit Hyperactivity Disorder, sponsored by Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province. Completed at 1 site in China. Open to participants aged 8 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jan 2024, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
8 Years to 15 Years
Sex
All
01

Study summary

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition in children and adolescents and is often associated with difficulties in attention, behavior regulation, and executive functioning. In addition to medication, non-pharmacological interventions, including digital and technology-assisted educational approaches, have gained increasing interest.

This randomized controlled trial compared the effects of artificial intelligence (AI)-assisted teaching and immersive virtual reality (VR)-based smart classroom teaching on core ADHD symptoms and executive function in children and adolescents with ADHD. A total of 90 participants aged 8 to 15 years who met diagnostic criteria for ADHD were randomly assigned to either an AI-assisted teaching group or a VR-based teaching group.

Both groups received structured teaching interventions for 12 weeks, three sessions per week, with each session lasting 45 minutes. ADHD symptoms and executive function were assessed before the intervention, at the end of the intervention, and at a 3-month follow-up using validated rating scales.

The purpose of this study was to evaluate and compare the effectiveness of these two digital teaching approaches and to provide evidence for personalized, non-pharmacological educational interventions for children and adolescents with ADHD.

Read the detailed description

This study was an open-label, randomized, parallel-group controlled trial designed to compare the effects of artificial intelligence (AI)-assisted teaching and immersive virtual reality (VR)-based smart classroom teaching on core symptoms and executive function in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Participants aged 8 to 15 years were recruited from an outpatient ADHD clinic and were required to meet diagnostic criteria for ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Eligible participants were randomly assigned in a 1:1 ratio to either the AI-assisted teaching group or the VR-based teaching group using a computer-generated randomization sequence prepared by an independent statistician. Due to the nature of the digital interventions, participants were not blinded to group allocation; however, outcome assessments were conducted by trained evaluators who were blinded to treatment assignment.

Both groups received structured teaching interventions for 12 weeks, with three sessions per week and each session lasting approximately 45 minutes. The AI-assisted teaching intervention was delivered using a tablet-based adaptive learning system incorporating eye-tracking, behavioral analysis, and real-time feedback to dynamically adjust task difficulty and learning pace based on individual performance and attention patterns. The VR-based teaching intervention was delivered using immersive virtual reality technology to simulate classroom and task-based learning scenarios, with an emphasis on interactive learning and emotional regulation in a low-distraction environment.

Primary outcomes included changes in core ADHD symptoms as measured by the ADHD Rating Scale (ADHD-RS). Secondary outcomes included changes in executive function assessed using the Behavior Rating Inventory of Executive Function (BRIEF), parent-report version. Outcome measures were assessed at baseline prior to intervention initiation, at the end of the 12-week intervention period, and at a 3-month post-intervention follow-up.

All study procedures were approved by the Ethics Committee of Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, and written informed consent was obtained from parents or legal guardians, with assent obtained from participating children when appropriate. The study was conducted in accordance with the principles of the Declaration of Helsinki.

02

Conditions studied

  • Attention Deficit Hyperactivity Disorder

Keywords

  • ADHD
  • Artificial Intelligence
  • Virtual Reality
  • Digital Education
  • Executive Function
  • Children and Adolescents
  • Randomized Controlled Trial
  • Non-Pharmacological Intervention
03

In context

Attention Deficit Disorder with Hyperactivity

1,514 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 255 are open to participants now.

This study's enrollment of 90 is above the median of 72 across 1,207 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.

Browse Attention Deficit Disorder with Hyperactivity studies →

Lead sponsor

Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children and adolescents aged 8 to 15 years.
  • Diagnosis of attention-deficit/hyperactivity disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by two qualified child psychiatrists.
  • Total score of 25 or higher on the ADHD Rating Scale (ADHD-RS).
  • Intelligence quotient (IQ) of 80 or above as assessed by the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV).
  • Stable clinical status for at least 30 days prior to enrollment, with adherence to standard first-line or second-line treatment regimens, and no planned changes in treatment during the study period.
  • Ability to participate in structured digital teaching sessions.
  • Written informed consent provided by a parent or legal guardian, with assent obtained from the participant when appropriate.

Exclusion criteria

Exclusion Criteria:

  • Presence of neurodevelopmental or neurological disorders other than ADHD, such as cerebral palsy or epilepsy.
  • Diagnosis of severe psychiatric disorders, including schizophrenia.
  • Significant sensory impairments (e.g., hearing impairment) that could interfere with study participation.
  • Lack of response to two or more different classes of ADHD medications.
  • History of suspected substance abuse or dependence within the past 6 months.
  • Physical conditions or motor impairments that would prevent participation in the teaching interventions.
  • Current suicidal ideation or severe suicidal behavior as determined by the investigator.
  • Receipt of other structured psychological or educational interventions during the study period.
  • Any other condition that, in the opinion of the investigator, would make participation in the study inappropriate.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    AI-Assisted Teaching Group

    Participants assigned to this arm received artificial intelligence-assisted teaching delivered through a tablet-based adaptive learning system. The intervention was conducted for 12 weeks, with three sessions per week and each session lasting approximately 45 minutes. The system incorporated real-time feedback and adaptive task adjustment based on individual learning performance and attention patterns.

    Behavioral: Artificial Intelligence-Assisted Teaching

  • Experimental
    Virtual Reality Smart Classroom Group

    Participants assigned to this arm received immersive virtual reality-based smart classroom teaching. The intervention was delivered using VR technology to simulate interactive learning scenarios in a low-distraction environment. The program was conducted for 12 weeks, with three sessions per week and each session lasting approximately 45 minutes.

    Behavioral: Virtual Reality-Based Smart Classroom Teaching

Interventions

  • BehavioralArtificial Intelligence-Assisted Teaching

    A behavioral digital teaching intervention delivered through an artificial intelligence-assisted adaptive learning system. The system dynamically adjusted task difficulty and learning pace based on individual performance and attention-related behavioral data and provided real-time feedback during learning activities. The intervention was administered for 12 weeks, three sessions per week, with each session lasting approximately 45 minutes.

  • BehavioralVirtual Reality-Based Smart Classroom Teaching

    A behavioral teaching intervention delivered using immersive virtual reality technology to simulate interactive classroom and task-based learning scenarios. Participants engaged in structured learning activities within a low-distraction virtual environment designed to enhance attention and engagement. The intervention was conducted for 12 weeks, three sessions per week, with each session lasting approximately 45 minutes.

06

What researchers measure

Primary outcomes

  1. Change in Core ADHD Symptoms Measured by the ADHD Rating Scale (ADHD-RS)

    Core symptoms of attention-deficit/hyperactivity disorder (ADHD) were assessed using the ADHD Rating Scale (ADHD-RS), which includes subscales for inattention and hyperactivity/impulsivity. Higher scores indicate greater symptom severity. The scale was completed by trained evaluators based on standardized assessment procedures.

    Time frame: Baseline and at the end of the 12-week intervention period

Secondary outcomes

  1. Change in Executive Function Measured by the Behavior Rating Inventory of Executive Function (BRIEF)

    Executive function was assessed using the parent-report version of the Behavior Rating Inventory of Executive Function (BRIEF), which evaluates multiple domains including inhibition, working memory, planning/organization, and emotional control. Higher scores indicate greater impairment in executive function.

    Time frame: Baseline, at the end of the 12-week intervention period, and at the 3-month post-intervention follow-up

  2. Change in Inattention Symptoms Measured by the ADHD Rating Scale (ADHD-RS) Inattention Subscale

    Inattention symptoms were assessed using the inattention subscale of the ADHD Rating Scale (ADHD-RS). The subscale consists of items evaluating attention-related difficulties, with higher scores indicating more severe inattention symptoms.

    Time frame: Baseline, at the end of the 12-week intervention period, and at the 3-month post-intervention follow-up

  3. Change in Hyperactivity/Impulsivity Symptoms Measured by the ADHD Rating Scale (ADHD-RS) Hyperactivity/Impulsivity Subscale

    Hyperactivity and impulsivity symptoms were assessed using the hyperactivity/impulsivity subscale of the ADHD Rating Scale (ADHD-RS). Higher scores reflect greater severity of hyperactivity and impulsivity symptoms.

    Time frame: Baseline, at the end of the 12-week intervention period, and at the 3-month post-intervention follow-up

07

Study locations

1 site
  • Hongxinkang New Traditional Chinese Medicine Hospital, Tongren
    Tongren, Guizhou 554300, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07392463
Lead sponsor
Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province
Responsible party
Ning Li (Principal Investigator, Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province) — Principal investigator
First posted
Feb 6, 2026
Start date
Jan 1, 2024
Primary completion
Jan 31, 2025
Completion
Sep 30, 2025
Last update
Feb 6, 2026

Study contacts

Ning Li, PhD
principal investigator · Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion